Form 4: Syndax CFO to Acquire Shares via ESPP

Syndax Pharmaceuticals' Chief Financial Officer, Keith A. Goldan, will acquire 1,226 shares of common stock at $8.43 per share on July 31, 2025, through the company's Employee Stock Purchase Plan.

Summary

• Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals Inc. (SNDX), will acquire 1,226 shares of common stock.
• The acquisition is scheduled for July 31, 2025, at a price of $8.43 per share.
• This transaction is being made pursuant to the Issuer's Employee Stock Purchase Plan (ESPP).
• Following this acquisition, Goldan will directly own 93,676 shares of Syndax Pharmaceuticals common stock.
• This Form 4 filing is a voluntary report of this future acquisition.

Sentiment

Score: 7

Explanation: The filing reports a routine acquisition of shares by a key executive through an Employee Stock Purchase Plan. While not a large open-market purchase, it indicates continued insider ownership and participation in company equity programs, which is generally viewed as a positive sign of alignment and confidence.

Positives

• Management (CFO) is increasing their direct ownership in the company, which can signal confidence in future performance.
• The acquisition is part of an Employee Stock Purchase Plan, indicating a structured, long-term investment by an insider.

Future Outlook

The filing reports a future acquisition of shares by the Chief Financial Officer, indicating a pre-planned transaction under an employee benefit plan. It does not provide broader forward-looking statements or guidance on company performance.

Management Comments

• The reporting person is voluntarily filing this Form 4 to report the acquisition of shares pursuant to the Issuer's Employee Stock Purchase Plan.

Industry Context

This Form 4 filing details an individual insider transaction (CFO acquiring shares) and does not provide broader industry context or trends. Such transactions are common across industries as part of employee compensation and benefit plans.

Comparison to Industry Standards

• This transaction is an acquisition of shares by a corporate officer through an Employee Stock Purchase Plan (ESPP), which is a standard benefit offered by many publicly traded companies across various sectors.
• The specific price and number of shares are unique to this individual and company, but the mechanism of acquisition via an ESPP is a common practice for encouraging employee ownership and alignment with shareholder interests.

Related Party Transactions

• The acquisition of shares by the Chief Financial Officer through the company's Employee Stock Purchase Plan constitutes a related party transaction, as it involves a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Increased insider ownership may signal confidence, potentially aligning management interests with shareholders.
• Employees: Reinforces the company's commitment to employee stock ownership plans.

Next Steps

• The acquisition of 1,226 shares by Keith A. Goldan is scheduled to occur on July 31, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned acquisition of a relatively small number of shares by the CFO through an Employee Stock Purchase Plan. While insider buying can be a positive signal, this specific transaction is not indicative of a significant strategic shift or a strong market-beating opportunity. It primarily reflects participation in a standard employee benefit program. Therefore, it does not warrant a change in investment stance based solely on this filing.

Keywords

Syndax Pharmaceuticals, SNDX, Keith A. Goldan, Chief Financial Officer, CFO, Stock acquisition, Employee Stock Purchase Plan, ESPP, Insider trading, Form 4, Common stock